Carna Biosciences (TSE:4572) Cyclically Adjusted PS Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4572 Carna Biosciences Inc TSE:4572
42 GF Score
Price 円303.00
GF Value 円186.19
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Carna Biosciences  (TSE:4572) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Carna Biosciences Cyclically Adjusted PS Ratio Related Terms


Carna Biosciences Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Cyclically Adjusted PS Ratio Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.99 4.04 4.00 0.00 0.00

Carna Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.17 2.67 0.00 0.00 0.00

TSE:4572 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Carna Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Cyclically Adjusted PS Ratio falls into.


TSE:4572
42GF Score
Carna Biosciences Inc TSE:4572
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Carna Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, Carna Biosciences's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Carna Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 30.691 98.100 35.353
201603 25.086 97.900 28.955
201606 23.545 98.100 27.121
201609 14.995 98.000 17.290
201612 24.936 98.400 28.636
201703 21.148 98.100 24.360
201706 14.037 98.500 16.103
201709 16.400 98.800 18.757
201712 18.240 99.400 20.736
201803 22.106 99.200 25.181
201806 19.535 99.200 22.253
201809 19.442 99.900 21.991
201812 16.554 99.700 18.762
201903 16.622 99.700 18.839
201906 211.390 99.800 239.349
201909 35.023 100.100 39.536
201912 29.371 100.500 33.024
202003 27.717 100.300 31.227
202006 19.727 99.900 22.314
202009 21.603 99.900 24.436
202012 23.035 99.300 26.213
202103 18.648 99.900 21.093
202106 15.986 99.500 18.155
202109 15.741 100.100 17.770
202112 103.773 100.100 117.146
202203 41.235 101.100 46.089
202206 20.851 101.800 23.145
202209 18.740 103.100 20.539
202212 20.487 104.100 22.239
202303 14.329 104.400 15.509
202306 16.005 105.200 17.192
202309 12.291 106.200 13.078
202312 53.332 106.800 56.428
202403 10.549 107.200 11.120
202406 7.467 108.200 7.798
202412 0.000 110.700 0.000
202503 7.505 111.100 7.633
202506 5.642 111.700 5.708
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円303.00 is trading 62.7% above its estimated GF Value™ of 円186.19. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円186.19 vs. price of 円303.00 (62.7% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
42GF Score

Get the complete analysis for TSE:4572

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円303.00
Price
円186.19
GF Value